查看購物車
  • English
  • Japanese
  • Korean
全球疫苗市場：依適應症、技術、類型、給藥途徑、最終用戶和地區分類－預測至2031年
市場調查報告書
商品編碼
2115777

全球疫苗市場：依適應症、技術、類型、給藥途徑、最終用戶和地區分類－預測至2031年

Vaccines Market by Technology, Type, Disease, ROA, Competition - Global Forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 440 Pages | 訂單完成後即時交付

價格

預計到 2031 年，疫苗市場規模（不包括 COVID-19）將從 2026 年的 556.8 億美元成長至 711.4 億美元，預測期內複合年成長率為 5.0%。

調查範圍
調查期 2026-2031
基準年 2025
預測期 2026-2031
計算單位 金額（10億美元）
部分 按適應症、技術、類型、給藥途徑、最終用戶和地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

傳染病高發病率、疫苗技術創新、政府對疫苗研發的支持和大量資金投入、擴大免疫接種工作以及對投資和推出創新產品的重視等因素正在推動疫苗市場的成長。

疫苗市場-IMG1

按疾病分類，預計到 2025 年，肺炎鏈球菌疫苗將佔據疫苗市場最大的佔有率。

依疾病分類，疫苗市場可分為聯合疫苗、人類乳突病毒（HPV）疫苗、腦膜炎雙球菌病菌感染疫苗、帶狀皰疹疫苗、肺炎鏈球菌感染疫苗、流感疫苗、水痘疫苗、肝炎疫苗、百白破疫苗、脊髓灰質炎、新冠肺炎疫苗和其他疾病疫苗。預計到2025年，肺炎球菌疫苗將佔據疫苗市場最大佔有率。這主要歸因於幾個關鍵因素，包括全球肺炎鏈球菌感染發生率的上升、政府對免疫接種計畫的投入增加，以及公眾對肺炎球菌相關併發症（如肺炎、腦膜炎和血流感染）嚴重健康風險的認知不斷提高。此外，持續的技術創新和新一代肺炎鏈球菌疫苗（例如近期核准的20價和21價結合疫苗）的研發，正在拓展免疫接種選擇，進一步推動市場成長並帶來公共衛生效益。

按類型分類，預計到 2025 年，多價疫苗將佔據疫苗市場最大的佔有率。

疫苗市場按類型可分為單價疫苗和多價疫苗。預計到2025年，多價疫苗將佔據疫苗市場最大佔有率。其主導地位源自於多價疫苗只需一劑即可預防多種疾病。這減少了注射次數，簡化了接種流程，提高了患者依從性，並減輕了物流方面的挑戰。此外，呼吸道感染疾病和某些癌症等需要廣譜免疫的疾病日益普遍，也推動了這類疫苗的需求。技術進步和對多價疫苗高效生產投入的增加進一步促進了這一趨勢，使得更大規模、更快的生產成為可能。醫療資源匱乏地區的政府和醫療機構尤其青睞多價疫苗，因為簡化接種程序有助於提高疫苗接種率，進而改善公共衛生狀況。

預計2026年至2031年，亞太地區疫苗市場將經歷最高的複合年成長率。

疫苗市場按地區分類為北美、歐洲、亞太、拉丁美洲以及中東和非洲。預計亞太地區在預測期內將以顯著的複合年成長率成長。這一成長主要得益於公眾健康意識的提高、國家免疫規劃的擴展以及政府對醫療基礎設施投入的增加。支撐這些努力的是官民合作關係、旨在提高疫苗公平性的國際合作以及能夠促進先進疫苗研發和降低生產成本的技術進步。此外，該地區龐大且持續成長的人口，尤其是在中國和印度等國家，為現有疫苗和新型疫苗提供了巨大的目標市場。這些因素凸顯了亞太地區在疫苗產業市場的主導地位。

一些主要的疫苗供應商包括輝瑞公司（美國）、葛蘭素史克公司（英國）、默克公司（美國）、賽諾菲（法國）、CSL（澳洲）、Emergent（美國）、強生服務公司（美國）、阿斯特捷利康（英國）、印度血清研究所。 Ltd.（印度）、Bavarian Nordic（丹麥）、三菱田邊製藥株式會社（日本）、第一三共株式會社（日本）、Panacea Biotec（印度）、Biological E. Limited（印度）、Bharat Biotech（印度）、Novavax（美國）、Inovio Pharmaceuticals（美國）、科興氏生物（中國）、孟加拉）、大眾（中國）、FBIuticals（美國）、科興生物（中國）、FBIuticals（中國）、Aakutical） Vaccines Inc.（美國）、Bio Farma（印尼）、FSUE NPO Microgen（俄羅斯）、智飛生物（中國）和Indian Immunologicals Ltd.（印度）。

調查範圍

本研究報告按技術（結合疫苗、重組疫苗、去活化/次單位疫苗、減毒活病毒疫苗、類毒素疫苗和其他疫苗）、類型（單價疫苗和多價疫苗）、適應症（肺炎鏈球菌感染、流感、聯合疫苗、HPV、腦膜炎雙球菌病菌感染、帶狀皰疹、輪狀病毒、麻疹-腮腺炎-德國麻疹複合疫苗、脊髓灰質炎、肝血化疫苗和其他疾病適應症）、給藥途徑（肌肉/皮下注射、口服和其他給藥途徑）、最終用戶（兒童疫苗和成人疫苗）以及地區（北美、歐洲、亞太地區、拉丁美洲、中東和非洲）對疫苗市場進行細分。

本報告詳細概述了影響疫苗市場成長的關鍵因素，包括促進因素、挑戰、機會和限制因素。該報告對主要行業參與者進行了全面分析，深入剖析了他們的業務概況、產品系列和關鍵策略，包括夥伴關係、擴張、協議、收購以及與疫苗市場相關的最新進展。該報告還對疫苗市場生態系統中的主要參與者和新興新創公司進行了競爭分析。此外，報告詳細闡述了塑造市場成長的關鍵因素——促進因素、限制因素、挑戰和機會——並深入分析了主要行業參與者的解決方案、產品、近期產品發布、併購以及新興市場趨勢和生態系統。

購買本報告的主要好處

本報告全面概​​述了疫苗市場，旨在評估疫苗市場規模及未來成長機遇，並分析了技術、類型、適應症、給藥途徑、最終用戶和地區等各個細分市場的情況。此外，該報告還對主要市場參與者進行了詳細的競爭分析，包括公司簡介、近期發展動態和關鍵市場策略。

本報告深入分析了以下幾點：

對關鍵促進因素（重點關注疫苗的研發和上市、感染疾病疫情的蔓延、免疫接種計劃的成長、疫苗技術的進步以及政府對疫苗研發的支持和資金）、阻礙因素（疫苗研發高成本）、機遇（對治療性疫苗的日益重視、疫苗的廣泛研發以及對臨床試驗投入的增加）和挑戰（嚴格的監管流程（嚴格的監管和產品）進行分析。

  • 產品開發/創新：對新推出的產品進行詳細分析，並對疫苗市場進行技術評估。
  • 市場發展：提供盈利市場的全面資訊。本報告分析了各地區的疫苗市場。
  • 市場多元化：疫苗市場新興和未開發地區、最新趨勢和投資機會的全面資訊。

競爭分析：主要競爭對手包括輝瑞公司（美國）、葛蘭素史克公司（英國）、默克公司（美國）、賽諾菲（法國）、CSL（澳洲）、Emergent（美國）、強生服務公司（美國）、阿斯特捷利康（英國）、印度血清研究所私人有限公司。有限公司（印度）、巴伐利亞北歐公司（丹麥）、三菱田邊製藥株式會社（日本）、第一三共株式會社（日本）、Panacea Biotec（印度）、Biological E. Limited（印度）、Bharat Biotech（印度）、Novavax（美國）、Inovio Pharmaceuticals（美國）、Valuticals（中國）、科興隆（美國）、Anov Vaccines Inc.（美國）、Bio Farma（印尼）、FSUE NPO Microgen（俄羅斯）、智飛生物（中國）、Indian Immunologicals Ltd.（印度）等。

此外，本報告有助於相關人員了解疫苗市場趨勢，並提供關鍵市場促進因素、限制因素、挑戰和機會的資訊。該報告對主要行業參與者進行了詳細分析，深入剖析了他們的關鍵策略、產品發布和核准情況、研發管線現狀、收購、合作、合資企業、近期活動、投資和資金籌措、品牌和產品對比、供應商評估以及疫苗市場的財務指標。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和未開發的領域
  • 相互關聯的市場與跨產業機遇
  • 一級/二級/三級公司的策略性舉措

第5章 產業趨勢

  • 波特五力分析
  • 宏觀經濟展望
  • 價值鏈分析
  • 管道分析
  • 生態系分析
  • 價格分析
  • 貿易分析
  • 2026-2027 年主要會議和活動
  • 影響客戶業務的趨勢/顛覆性因素
  • 投資和資金籌措場景
  • 2025年美國關稅對疫苗市場的影響
  • 疫苗採購數據
  • 疫苗生產過程

第6章：技術進步、人工智慧的影響、專利與創新

  • 技術分析
  • 技術/產品藍圖
  • 專利分析
  • 未來應用
  • 人工智慧/人工智慧產生的疫苗市場的影響

第7章：監理情勢與永續性舉措

  • 當地法規和合規性
  • 對永續性的承諾
  • 監管政策對永續性的影響
  • 認證、標籤檢視和環境標準

第8章：顧客趨勢與購買行為

  • 決策流程
  • 買方相關人員和採購評估標準
  • 實施障礙和內部挑戰
  • 各個終端用戶產業尚未滿足的需求
  • 市場盈利

第9章：依適應症分類的疫苗市場

  • 肺炎鏈球菌感染
  • 流感
  • HPV
  • 帶狀皰疹
  • 聯合疫苗
  • 病菌感染
  • 輪狀病毒
  • RSV
  • DTP
  • 肝炎
  • 水痘
  • MMR
  • 脊髓灰質炎
  • COVID-19
  • 其他

第10章：按技術分類的疫苗市場

  • 疫苗市場（不包括新冠疫苗），依技術分類
    • 重組疫苗
    • 結合疫苗
    • 去活化疫苗和次單位疫苗
    • 活病毒疫苗
    • 類毒素疫苗
    • 其他疫苗
  • 新冠疫苗市場（依技術分類）
    • 藥效疫苗
    • 病毒載體疫苗
    • 其他新冠疫苗

第11章：疫苗市場（不包括新冠疫苗），依類型分類

  • 多價疫苗
  • 疫苗單價

第12章：疫苗市場（不包括新冠疫苗），依給藥途徑分類

  • 肌肉注射和皮下注射
  • 口服
  • 其他

第13章：疫苗市場（不包括新冠疫苗），依最終用戶分類

  • 成人疫苗
  • 兒童疫苗

第14章：疫苗市場（不含新冠疫苗），依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東
  • 非洲

第15章 競爭格局

  • 概述
  • 主要參與企業的策略/優勢
  • 2021-2025年收入分析
  • 2025年市佔率分析
  • 企業估值矩陣：主要公司，2025 年
  • 公司估值矩陣：新創企業/中小企業，2025 年
  • 企業估值和財務指標
  • 產品對比
  • 競爭格局

第16章：公司簡介

  • 主要參與企業
    • PFIZER INC.
    • GSK PLC
    • MERCK & CO., INC.
    • SANOFI
    • CSL
    • EMERGENT
    • JOHNSON & JOHNSON SERVICES, INC.
    • ASTRAZENECA
    • SERUM INSTITUTE OF INDIA PVT. LTD.
    • BAVARIAN NORDIC
    • TANABE PHARMA CORPORATION
    • DAIICHI SANKYO COMPANY, LIMITED
    • PANACEA BIOTEC
    • BIOLOGICAL E. LIMITED
    • BHARAT BIOTECH
    • NOVAVAX
    • INOVIO PHARMACEUTICALS
  • 其他公司
    • SINOVAC
    • INCEPTA PHARMACEUTICALS LTD.
    • VALNEVA SE
    • EUBIOLOGICS CO., LTD.
    • BIO FARMA
    • MICROGEN
    • CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
    • INDIAN IMMUNOLOGICALS LIMITED

第17章調查方法

第18章附錄

Product Code: PH 6528

The vaccines market (excluding COVID-19) is expected to reach USD 71.14 billion in 2031, up from USD 55.68 billion in 2026, growing at a CAGR of 5.0% during the forecast period.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsTechnology, Type, Disease Indication, Route of Administration, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Factors such as the high incidence of contagious diseases, innovation in vaccine technology, government support and substantial funding for vaccine development, increasing vaccination initiatives, and a strong focus on investing in and launching innovative products are driving this growth in vaccines.

Vaccines Market - IMG1

By disease indication, the pneumococcal segment accounted for the largest share of the vaccines market in 2025.

Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. In 2025, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits.

By type, the multivalent vaccines segment accounted for the largest share of the vaccines market in 2025.

The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2025, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance stems from multivalent vaccines' ability to protect against multiple diseases with a single dose-simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.

The Asia Pacific region is expected to grow at the highest CAGR in the vaccines market from 2026 to 2031.

The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public-private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region's large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific's leadership in the vaccine industry market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side (80%) and Demand Side (20%)
  • By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
  • By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Pfizer, Inc. (US), GSK Plc (UK), Merck & Co., Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi Fei Biological (China), and Indian Immunologicals Ltd. (India) are some of the key companies offering vaccines.

Research Coverage

This research report categorizes the vaccines market by technology (conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines), type (monovalent vaccines and multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV, COVID-19, and other disease indications), route of administration (intramuscular & subcutaneous administration, oral administration, and other routes of administration), end user (pediatric vaccines and adult vaccines), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).

The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. This report includes a competitive analysis of top players and upcoming startups within the vaccines market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players' solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.

Key Benefits of Buying the Report

This report offers a comprehensive overview of the vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.

The report provides insights into the following pointers:

Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, and government support & funding for vaccine development), restraints (high cost of vaccine development), opportunities (rising focus on therapeutic vaccines, extensive R&D for vaccines, and increased investments in clinical trials), and challenges (stringent regulatory processes and product recalls)

  • Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the vaccines market.
  • Market Development: Comprehensive information about lucrative markets; the report analyzes the vaccines market across varied regions.
  • Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the vaccines market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi Fei Biological (China), and Indian Immunologicals Ltd (India), among others, in the vaccines market.

The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments and funding, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONS COVERED
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN VACCINES MARKET
  • 2.4 HIGH-GROWTH SEGMENTS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 VACCINES MARKET OVERVIEW
  • 3.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE AND COUNTRY, 2025
  • 3.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES
  • 3.4 VACCINES MARKET (EXCLUDING COVID-19 VACCINES) SHARE, BY ROUTE OF ADMINISTRATION, 2026 VS 2031 (%)

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Focus on vaccine development and launches
      • 4.2.1.2 Rising prevalence of infectious diseases
      • 4.2.1.3 Increasing immunization programs
      • 4.2.1.4 Advancements in vaccine technology
      • 4.2.1.5 Government support and funding for vaccine development
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High cost of vaccine development
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Rising focus on therapeutic vaccines
      • 4.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Stringent regulatory processes
      • 4.2.4.2 Product recalls
  • 4.3 UNMET NEEDS & WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
    • 5.2.3 TRENDS IN GLOBAL VACCINES INDUSTRY
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 PIPELINE ANALYSIS
    • 5.4.1 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
    • 5.4.2 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
    • 5.4.3 VACCINES MARKET: PHASE 2/3 CLINICAL TRIALS, BY COMPANY
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024-2026
    • 5.6.2 AVERAGE SELLING PRICE TREND, BY DISEASE INDICATION, 2024-2026
    • 5.6.3 AVERAGE SELLING PRICE TREND, BY REGION, 2022-2024
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT SCENARIO (HS CODE 300220)
    • 5.7.2 EXPORT SCENARIO (HS CODE 300220)
  • 5.8 KEY CONFERENCES AND EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
  • 5.10 INVESTMENT AND FUNDING SCENARIO
    • 5.10.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
  • 5.11 IMPACT OF 2025 US TARIFFS-VACCINES MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON COUNTRIES/REGIONS
      • 5.11.4.1 US
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
    • 5.11.5 IMPACT ON END-USE INDUSTRIES
      • 5.11.5.1 Public health & government bodies
      • 5.11.5.2 Healthcare providers & institutions
  • 5.12 VACCINE PROCUREMENT DATA
    • 5.12.1 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024-2026
    • 5.12.2 WHO: VACCINE PURCHASE DATABASE, 2022-2024
  • 5.13 VACCINE MANUFACTURING PROCESS
    • 5.13.1 OVERVIEW
      • 5.13.1.1 R&D and process development
      • 5.13.1.2 Upstream production (antigen generation)
      • 5.13.1.3 Downstream processing
      • 5.13.1.4 Formulation & fill-finish
      • 5.13.1.5 Quality control & regulatory release
      • 5.13.1.6 Packaging, cold chain, and distribution
    • 5.13.2 MANUFACTURING MODELS & CAPACITY DYNAMICS

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS

  • 6.1 TECHNOLOGY ANALYSIS
    • 6.1.1 KEY EMERGING TECHNOLOGIES
      • 6.1.1.1 Recombinant technology
      • 6.1.1.2 Conjugation technology
      • 6.1.1.3 Viral vector technology
    • 6.1.2 COMPLEMENTARY TECHNOLOGIES
      • 6.1.2.1 Encapsulation & delivery technology
      • 6.1.2.2 Automation & control
      • 6.1.2.3 AI & machine learning for vaccine design
    • 6.1.3 ADJACENT TECHNOLOGIES
      • 6.1.3.1 Single-use technology
      • 6.1.3.2 Cell line development
  • 6.2 TECHNOLOGY/PRODUCT ROADMAP
  • 6.3 PATENT ANALYSIS
    • 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS
  • 6.4 FUTURE APPLICATIONS
  • 6.5 IMPACT OF AI/GEN AI-VACCINES MARKET
    • 6.5.1 BEST PRACTICES IN VACCINES WORKFLOW
    • 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET
    • 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
    • 6.5.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN VACCINES MARKET

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 REGULATORY FRAMEWORK
      • 7.1.2.1 North America
      • 7.1.2.2 Europe
      • 7.1.2.3 Asia Pacific
      • 7.1.2.4 Latin America
      • 7.1.2.5 Middle East & Africa
    • 7.1.3 REGULATORY CHALLENGES IN VACCINES MARKET
    • 7.1.4 INDUSTRY STANDARDS
  • 7.2 SUSTAINABILITY INITIATIVES
  • 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY
  • 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 KEY BUYING CRITERIA, BY END USER
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY

9 VACCINES MARKET, BY DISEASE INDICATION

  • 9.1 INTRODUCTION
  • 9.2 PNEUMOCOCCAL DISEASE
    • 9.2.1 EXPANDING ADULT IMMUNIZATION PROGRAMS AND HIGHER-VALENCY VACCINES TO DRIVE MARKET
  • 9.3 INFLUENZA
    • 9.3.1 SEASONAL IMMUNIZATION PROGRAMS AND EXPANDING ADULT VACCINATION TO DRIVE MARKET
  • 9.4 HPV
    • 9.4.1 EXPANDING NATIONAL HPV IMMUNIZATION PROGRAMS AND RISING ADOPTION OF GENDER-NEUTRAL VACCINATION TO DRIVE THE FASTEST-GROWING SEGMENT
  • 9.5 HERPES ZOSTER
    • 9.5.1 RISING AGING POPULATION TO DRIVE DEMAND FOR HERPES ZOSTER VACCINES
  • 9.6 COMBINATION VACCINES
    • 9.6.1 EXPANDING NATIONAL IMMUNIZATION PROGRAMS AND GROWING PREFERENCE FOR MULTI-ANTIGEN VACCINES TO DRIVE MARKET
  • 9.7 MENINGOCOCCAL DISEASE
    • 9.7.1 EXPANDING IMMUNIZATION RECOMMENDATIONS AND BROADER SEROGROUP COVERAGE TO SUPPORT MARKET GROWTH
  • 9.8 ROTAVIRUS
    • 9.8.1 RISING INFANT IMMUNIZATION PROGRAMS TO DRIVE ROTAVIRUS MARKET GROWTH
  • 9.9 RSV
    • 9.9.1 INITIAL VACCINE UPTAKE AND EXPANDING IMMUNIZATION RECOMMENDATIONS SUPPORT MARKET PENETRATION
  • 9.10 DTP
    • 9.10.1 CONTINUED ROUTINE CHILDHOOD IMMUNIZATION AND BOOSTER VACCINATION PROGRAMS TO SUPPORT MARKET
  • 9.11 HEPATITIS
    • 9.11.1 EXPANDING HEPATITIS B IMMUNIZATION AND GLOBAL ELIMINATION INITIATIVES TO SUPPORT MARKET GROWTH
  • 9.12 VARICELLA
    • 9.12.1 EXPANDING CHILDHOOD IMMUNIZATION PROGRAMS AND INCREASING ADOPTION OF VARICELLA VACCINES TO SUPPORT MARKET GROWTH
  • 9.13 MMR
    • 9.13.1 RISING MEASLES OUTBREAKS AND IMMUNIZATION RECOVERY EFFORTS TO SUPPORT MARKET GROWTH
  • 9.14 POLIO
    • 9.14.1 GLOBAL POLIO ERADICATION INITIATIVES AND CONTINUED VACCINATION CAMPAIGNS TO SUSTAIN MARKET DEMAND
  • 9.15 COVID-19
    • 9.15.1 SHIFT FROM PANDEMIC-DRIVEN DEMAND TO ENDURING HIGH-RISK POPULATION VACCINATION, RESULTING IN MARKET NORMALIZATION
  • 9.16 OTHER DISEASE INDICATIONS

10 VACCINES MARKET, BY TECHNOLOGY

  • 10.1 INTRODUCTION
  • 10.2 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY
    • 10.2.1 RECOMBINANT VACCINES
      • 10.2.1.1 Broader adult immunization and continued recombinant vaccine launches to drive market
    • 10.2.2 CONJUGATE VACCINES
      • 10.2.2.1 Higher-valency pneumococcal vaccines and large public immunization programs to drive market
    • 10.2.3 INACTIVATED & SUBUNIT VACCINES
      • 10.2.3.1 Recurring influenza demand and wider access to established non-live vaccines to support market
    • 10.2.4 LIVE ATTENUATED VACCINES
      • 10.2.4.1 Durable immune protection and convenient oral or nasal administration to support market
    • 10.2.5 TOXOID VACCINES
      • 10.2.5.1 Routine pediatric boosters and maternal immunization programs to sustain market
    • 10.2.6 OTHER VACCINES
  • 10.3 COVID-19 VACCINES MARKET, BY TECHNOLOGY
    • 10.3.1 MRNA VACCINES
      • 10.3.1.1 Rapid variant adaptation and continued vaccination of high-risk populations to drive market
    • 10.3.2 VIRAL VECTOR VACCINES
      • 10.3.2.1 Withdrawal of first-generation products and shift toward updated vaccine platforms to accelerate market decline
    • 10.3.3 OTHER COVID-19 VACCINES

11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE

  • 11.1 INTRODUCTION
  • 11.2 MULTIVALENT VACCINES
    • 11.2.1 BROADER SEROTYPE COVERAGE AND INCREASING ADOPTION OF COMBINATION IMMUNIZATION SCHEDULES TO DRIVE MARKET
  • 11.3 MONOVALENT VACCINES
    • 11.3.1 ESTABLISHED SINGLE-DISEASE PROGRAMS AND EXPANDING ADULT IMMUNIZATION INDICATIONS TO SUPPORT MARKET

12 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION

  • 12.1 INTRODUCTION
  • 12.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
    • 12.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION
  • 12.3 ORAL ADMINISTRATION
    • 12.3.1 NEEDLE-FREE DELIVERY AND HIGH-VOLUME DISEASE-CONTROL CAMPAIGNS TO SUPPORT MARKET
  • 12.4 OTHER ROUTES OF ADMINISTRATION

13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER

  • 13.1 INTRODUCTION
  • 13.2 ADULT VACCINES
    • 13.2.1 AGING POPULATIONS, BROADER ADULT INDICATIONS, AND GROWING LIFE-COURSE IMMUNIZATION TO DRIVE MARKET
  • 13.3 PEDIATRIC VACCINES
    • 13.3.1 EXPANDING CHILDHOOD IMMUNIZATION SCHEDULES AND NEW VACCINE INTRODUCTIONS TO DRIVE MARKET GROWTH

14 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 US
      • 14.2.1.1 US to dominate North American market during forecast period
    • 14.2.2 CANADA
      • 14.2.2.1 Expansion of life-course immunization to support market growth
  • 14.3 EUROPE
    • 14.3.1 GERMANY
      • 14.3.1.1 Adult immunization and updated national recommendations to drive market growth
    • 14.3.2 UK
      • 14.3.2.1 Expansion of adult and maternal immunization programs to support market growth
    • 14.3.3 FRANCE
      • 14.3.3.1 Favorable government initiatives for mass immunization to drive market
    • 14.3.4 ITALY
      • 14.3.4.1 Higher investments by companies for increased production capacities to drive market
    • 14.3.5 SPAIN
      • 14.3.5.1 Rising investments in vaccine development by private organizations to drive market
    • 14.3.6 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 CHINA
      • 14.4.1.1 China to hold largest share of APAC vaccines market
    • 14.4.2 JAPAN
      • 14.4.2.1 Aging population and gradual expansion of routine vaccination to drive demand
    • 14.4.3 INDIA
      • 14.4.3.1 Large immunization requirements and manufacturing leadership to support strong growth
    • 14.4.4 SOUTH KOREA
      • 14.4.4.1 Strong government strategies for improved vaccine hubs to drive market
    • 14.4.5 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 BRAZIL
      • 14.5.1.1 Strong public procurement and domestic manufacturing to drive market
    • 14.5.2 MEXICO
      • 14.5.2.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth
    • 14.5.3 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST
    • 14.6.1 GOVERNMENT-LED LOCALIZATION AND EXPANDING ADULT AND TRAVEL IMMUNIZATION TO SUPPORT MARKET GROWTH
  • 14.7 AFRICA
    • 14.7.1 HIGH UNMET IMMUNIZATION NEEDS AND LOCAL MANUFACTURING INITIATIVES TO DRIVE MARKET EXPANSION

15 COMPETITIVE LANDSCAPE

  • 15.1 OVERVIEW
  • 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINES MARKET
  • 15.3 REVENUE ANALYSIS, 2021-2025
  • 15.4 MARKET SHARE ANALYSIS, 2025
  • 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 15.5.1 STARS
    • 15.5.2 EMERGING LEADERS
    • 15.5.3 PERVASIVE PLAYERS
    • 15.5.4 PARTICIPANTS
    • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 15.5.5.1 Company footprint
      • 15.5.5.2 Region footprint
      • 15.5.5.3 Technology footprint
      • 15.5.5.4 Type footprint
      • 15.5.5.5 Route of administration footprint
  • 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 15.6.1 PROGRESSIVE COMPANIES
    • 15.6.2 RESPONSIVE COMPANIES
    • 15.6.3 DYNAMIC COMPANIES
    • 15.6.4 STARTING BLOCKS
    • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
      • 15.6.5.1 Detailed list of key startups/SMEs
      • 15.6.5.2 Competitive benchmarking of key startups/SMEs
  • 15.7 COMPANY VALUATION & FINANCIAL METRICS
    • 15.7.1 FINANCIAL METRICS
    • 15.7.2 COMPANY VALUATION
  • 15.8 PRODUCT COMPARISON
    • 15.8.1 PRODUCT COMPARATIVE ANALYSIS
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT LAUNCHES & APPROVALS
    • 15.9.2 DEALS
    • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 PFIZER INC.
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product approvals
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Key strengths
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses & competitive threats
    • 16.1.2 GSK PLC
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Product launches & approvals
        • 16.1.2.3.2 Deals
        • 16.1.2.3.3 Expansions
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Key strengths
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses & competitive threats
    • 16.1.3 MERCK & CO., INC.
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Product approvals
        • 16.1.3.3.2 Expansions
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Key strengths
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses & competitive threats
    • 16.1.4 SANOFI
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Product approvals
        • 16.1.4.3.2 Deals
        • 16.1.4.3.3 Expansions
        • 16.1.4.3.4 Other developments
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Key strengths
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses & competitive threats
    • 16.1.5 CSL
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Product approvals
        • 16.1.5.3.2 Deals
        • 16.1.5.3.3 Expansions
    • 16.1.6 EMERGENT
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products offered
      • 16.1.6.3 Recent developments
        • 16.1.6.3.1 Product approvals
        • 16.1.6.3.2 Deals
        • 16.1.6.3.3 Other developments
    • 16.1.7 JOHNSON & JOHNSON SERVICES, INC.
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Deals
    • 16.1.8 ASTRAZENECA
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Deals
        • 16.1.8.3.2 Expansions
    • 16.1.9 SERUM INSTITUTE OF INDIA PVT. LTD.
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products offered
      • 16.1.9.3 Recent developments
        • 16.1.9.3.1 Product launches & approvals
        • 16.1.9.3.2 Deals
        • 16.1.9.3.3 Expansions
    • 16.1.10 BAVARIAN NORDIC
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Product approvals
        • 16.1.10.3.2 Deals
        • 16.1.10.3.3 Other developments
    • 16.1.11 TANABE PHARMA CORPORATION
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Product launches & approvals
        • 16.1.11.3.2 Deals
    • 16.1.12 DAIICHI SANKYO COMPANY, LIMITED
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products offered
      • 16.1.12.3 Recent developments
        • 16.1.12.3.1 Deals
    • 16.1.13 PANACEA BIOTEC
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products offered
      • 16.1.13.3 Recent developments
        • 16.1.13.3.1 Other developments
    • 16.1.14 BIOLOGICAL E. LIMITED
      • 16.1.14.1 Business overview
      • 16.1.14.2 Products offered
      • 16.1.14.3 Recent developments
        • 16.1.14.3.1 Product approvals
        • 16.1.14.3.2 Deals
        • 16.1.14.3.3 Other developments
    • 16.1.15 BHARAT BIOTECH
      • 16.1.15.1 Business overview
      • 16.1.15.2 Products offered
      • 16.1.15.3 Recent developments
        • 16.1.15.3.1 Product launches & approvals
        • 16.1.15.3.2 Deals
    • 16.1.16 NOVAVAX
      • 16.1.16.1 Business overview
      • 16.1.16.2 Products offered
      • 16.1.16.3 Recent developments
        • 16.1.16.3.1 Product approvals
        • 16.1.16.3.2 Deals
    • 16.1.17 INOVIO PHARMACEUTICALS
      • 16.1.17.1 Business overview
      • 16.1.17.2 Products offered
      • 16.1.17.3 Recent developments
        • 16.1.17.3.1 Other developments
  • 16.2 OTHER PLAYERS
    • 16.2.1 SINOVAC
    • 16.2.2 INCEPTA PHARMACEUTICALS LTD.
    • 16.2.3 VALNEVA SE
    • 16.2.4 EUBIOLOGICS CO., LTD.
    • 16.2.5 BIO FARMA
    • 16.2.6 MICROGEN
    • 16.2.7 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
    • 16.2.8 INDIAN IMMUNOLOGICALS LIMITED

17 RESEARCH METHODOLOGY

  • 17.1 RESEARCH DATA
    • 17.1.1 SECONDARY DATA
      • 17.1.1.1 Key secondary sources
      • 17.1.1.2 Key data from secondary research
    • 17.1.2 PRIMARY DATA
      • 17.1.2.1 Key primary participants
      • 17.1.2.2 Breakdown of primary interviews
      • 17.1.2.3 Key data from primary sources
  • 17.2 MARKET SIZE ESTIMATION
    • 17.2.1 GLOBAL VACCINES MARKET SIZE ESTIMATION, 2025
      • 17.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up approach)
      • 17.2.1.2 Approach 2: Primary research
        • 17.2.1.2.1 Key industry insights
      • 17.2.1.3 Approach 3: Secondary analysis
      • 17.2.1.4 Approach 4: Bottom-up approach (disease indication-based analysis)
      • 17.2.1.5 Approach 5: MarketsandMarkets repository analysis
    • 17.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH), 2025
  • 17.3 MARKET GROWTH RATE PROJECTIONS
  • 17.4 DATA TRIANGULATION
  • 17.5 RESEARCH ASSUMPTIONS
  • 17.6 RESEARCH LIMITATIONS & RISK ASSESSMENT

18 APPENDIX

  • 18.1 DISCUSSION GUIDE
  • 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 18.3 CUSTOMIZATION OPTIONS
  • 18.4 RELATED REPORTS
  • 18.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 VACCINES MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 VACCINES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 3 NIH FUNDING FOR VACCINE RESEARCH, 2020-2025 (USD MILLION)
  • TABLE 4 MAJOR COST DRIVERS AND IMPACT ON COST OF GOODS SOLD (COGS)
  • TABLE 5 NOTABLE CANCER VACCINES IN CLINICAL TRIALS
  • TABLE 6 VACCINES MARKET: IMPACT OF PORTER'S FIVE FORCES
  • TABLE 7 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR RSV
  • TABLE 8 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR CANCER
  • TABLE 9 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR INFLUENZA
  • TABLE 10 KEY PIPELINE VACCINES: GSK PLC
  • TABLE 11 KEY PIPELINE VACCINES: MERCK & CO., INC.
  • TABLE 12 KEY PIPELINE VACCINES: PFIZER INC.
  • TABLE 13 KEY PIPELINE VACCINES: SANOFI
  • TABLE 14 VACCINES MARKET: ROLE IN ECOSYSTEM
  • TABLE 15 AVERAGE SELLING PRICE TREND OF PEDIATRIC VACCINES, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 16 AVERAGE SELLING PRICE TREND OF ADULT VACCINES, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 17 AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2022-2024 (USD)
  • TABLE 18 IMPORT DATA FOR HS CODE 300220, 2021-2025 (USD THOUSAND)
  • TABLE 19 IMPORT DATA FOR HS CODE 300220, 2021-2025 (TONS)
  • TABLE 20 EXPORT DATA FOR HS CODE 300220, 2021-2025 (USD THOUSAND)
  • TABLE 21 EXPORT DATA FOR HS CODE 300220, 2021-2025 (TONS)
  • TABLE 22 VACCINES MARKET: KEY CONFERENCES AND EVENTS, 2026-2027
  • TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 24 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024-2026
  • TABLE 25 WHO VACCINE PURCHASE DATABASE, BY PROCUREMENT MECHANISM, 2022-2024
  • TABLE 26 WHO VACCINE PURCHASE DATABASE, BY MANUFACTURER, 2022-2024
  • TABLE 27 WHO VACCINE PURCHASE DATABASE, BY INDICATION, 2022-2024
  • TABLE 28 WHO VACCINE PURCHASE DATABASE, BY REGION, 2022-2024
  • TABLE 29 VACCINE PRODUCTION CAPACITY, BY KEY PLAYER, 2025
  • TABLE 30 KEY VACCINE MANUFACTURING CAPACITY EXPANSIONS, 2025-2026
  • TABLE 31 VACCINES MARKET: INDICATIVE LIST OF PATENTS, 2026
  • TABLE 32 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET
  • TABLE 33 CLIENT'S READINESS TO ADOPT GENERATIVE AI IN VACCINES
  • TABLE 34 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 35 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 36 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 37 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 38 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY VACCINES
  • TABLE 39 KEY BUYING CRITERIA, BY END USER
  • TABLE 40 VACCINES MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 41 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES
  • TABLE 42 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 43 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 44 EUROPE: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 46 LATIN AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 47 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES
  • TABLE 48 INFLUENZA VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 49 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 52 LATIN AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 53 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES
  • TABLE 54 HPV VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 56 EUROPE: HPV VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: HPV VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 58 LATIN AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 59 LIST OF COMMERCIALLY AVAILABLE HERPES ZOSTER VACCINES
  • TABLE 60 HERPES ZOSTER VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 61 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 62 EUROPE: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 64 LATIN AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 65 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES
  • TABLE 66 COMBINATION VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 67 NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 68 EUROPE: COMBINATION VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 69 ASIA PACIFIC: COMBINATION VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 70 LATIN AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES
  • TABLE 72 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 73 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 74 EUROPE: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 76 LATIN AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 77 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES
  • TABLE 78 ROTAVIRUS VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 79 NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 80 EUROPE: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 82 LATIN AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 83 LIST OF COMMERCIALLY AVAILABLE RSV VACCINES
  • TABLE 84 RSV VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 85 NORTH AMERICA: RSV VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 86 EUROPE: RSV VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: RSV VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 88 LATIN AMERICA: RSV VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 89 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES
  • TABLE 90 DTP VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 91 NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 92 EUROPE: DTP VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 ASIA PACIFIC: DTP VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 94 LATIN AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 95 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES
  • TABLE 96 HEPATITIS VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 97 NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 98 EUROPE: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 99 ASIA PACIFIC: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 100 LATIN AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 101 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES
  • TABLE 102 VARICELLA VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 103 NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 104 EUROPE: VARICELLA VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: VARICELLA VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 106 LATIN AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 107 TOP 10 COUNTRIES WITH MEASLES OUTBREAKS, JANUARY 2025-JULY 2025
  • TABLE 108 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES
  • TABLE 109 MMR VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 110 NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 111 EUROPE: MMR VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: MMR VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 113 LATIN AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 114 POLIO VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 115 NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 116 EUROPE: POLIO VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: POLIO VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 118 LATIN AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 119 COVID-19 VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 120 NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 121 EUROPE: COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 123 LATIN AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 124 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
  • TABLE 125 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 126 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 127 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 129 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 130 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 131 EXAMPLES OF RECOMBINANT VACCINES
  • TABLE 132 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 133 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 134 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 136 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 137 EXAMPLES OF CONJUGATE VACCINES
  • TABLE 138 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 139 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 140 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 141 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 142 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 143 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
  • TABLE 144 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 145 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 146 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 147 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 148 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 149 EXAMPLES OF LIVE ATTENUATED VACCINES
  • TABLE 150 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 151 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 152 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 154 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 155 EXAMPLES OF TOXOID VACCINES
  • TABLE 156 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 157 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 158 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 160 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 161 OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 162 NORTH AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 163 EUROPE: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 164 ASIA PACIFIC: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 165 LATIN AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 166 COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 167 MRNA COVID-19 VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 168 NORTH AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 169 EUROPE: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 170 ASIA PACIFIC: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 171 LATIN AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 172 VIRAL VECTOR COVID-19 VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 173 NORTH AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 174 EUROPE: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 176 LATIN AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 177 OTHER COVID-19 VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 178 NORTH AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 179 EUROPE: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 180 ASIA PACIFIC: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 181 LATIN AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 182 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 183 EXAMPLES OF MULTIVALENT VACCINES
  • TABLE 184 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 185 NORTH AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 186 EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 187 ASIA PACIFIC: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 188 LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 189 EXAMPLES OF MONOVALENT VACCINES
  • TABLE 190 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 191 NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 192 EUROPE: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 193 ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 194 LATIN AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 195 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 196 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
  • TABLE 197 VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 198 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 199 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 200 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 201 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 202 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 203 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 204 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 206 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 207 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 208 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 209 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 211 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 212 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 213 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 214 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 215 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 217 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 218 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 219 NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 220 EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 222 LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 223 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 224 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 225 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 226 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 228 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 229 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 230 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 231 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 232 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 233 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 234 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 235 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 236 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 237 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 238 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 239 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 240 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 241 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 242 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 243 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 244 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 245 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 246 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 247 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 248 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 249 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 250 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 251 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 252 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 253 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 254 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 255 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 256 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 257 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 258 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 259 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 260 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 261 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 262 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 263 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 264 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 265 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 266 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 267 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 268 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 269 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 270 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 271 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 272 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 273 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 274 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 275 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 276 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 277 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 278 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 279 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 280 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 281 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 282 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 283 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 284 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 285 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 286 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 287 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 288 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 289 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 290 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 291 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 292 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 293 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 294 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 295 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 296 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 297 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 298 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 299 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 300 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 301 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 302 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 303 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 304 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 305 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 306 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 307 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 308 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 309 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 310 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 311 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 312 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 313 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 314 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 315 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 316 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 317 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 318 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 319 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 320 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 321 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 322 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 323 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 324 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 325 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 326 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 327 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 328 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 329 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 330 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 331 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 332 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 333 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 334 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 335 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024-2031 (USD MILLION)
  • TABLE 336 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 337 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024-2031 (USD MILLION)
  • TABLE 338 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINES MARKET, JANUARY 2023-JULY 2025
  • TABLE 339 VACCINES MARKET: DEGREE OF COMPETITION
  • TABLE 340 VACCINES MARKET: REGION FOOTPRINT
  • TABLE 341 VACCINES MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 342 VACCINES MARKET: TYPE FOOTPRINT
  • TABLE 343 VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
  • TABLE 344 VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 345 VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 346 VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 347 VACCINES MARKET: DEALS, JANUARY 2023-JULY 2026
  • TABLE 348 VACCINES MARKET: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 349 PFIZER INC.: COMPANY OVERVIEW
  • TABLE 350 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 351 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 352 GSK PLC: COMPANY OVERVIEW
  • TABLE 353 GSK PLC: PRODUCTS OFFERED
  • TABLE 354 GSK PLC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 355 GSK PLC: DEALS, JANUARY 2023-JULY 2026
  • TABLE 356 GSK PLC: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 357 MERCK & CO., INC.: COMPANY OVERVIEW
  • TABLE 358 MERCK & CO., INC.: PRODUCTS OFFERED
  • TABLE 359 MERCK & CO., INC.: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 360 MERCK & CO., INC.: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 361 SANOFI: COMPANY OVERVIEW
  • TABLE 362 SANOFI: PRODUCTS OFFERED
  • TABLE 363 SANOFI: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 364 SANOFI: DEALS, JANUARY 2023-JULY 2026
  • TABLE 365 SANOFI: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 366 SANOFI: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 367 CSL: COMPANY OVERVIEW
  • TABLE 368 CSL: PRODUCTS OFFERED
  • TABLE 369 CSL: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 370 CSL: DEALS, JANUARY 2023-JULY 2026
  • TABLE 371 CSL: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 372 EMERGENT: COMPANY OVERVIEW
  • TABLE 373 EMERGENT: PRODUCTS OFFERED
  • TABLE 374 EMERGENT: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 375 EMERGENT: DEALS, JANUARY 2023-JULY 2026
  • TABLE 376 EMERGENT: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 377 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
  • TABLE 378 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 379 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 380 ASTRAZENECA: COMPANY OVERVIEW
  • TABLE 381 ASTRAZENECA: PRODUCTS OFFERED
  • TABLE 382 ASTRAZENECA: DEALS, JANUARY 2023-JULY 2026
  • TABLE 383 ASTRAZENECA: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 384 SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY OVERVIEW
  • TABLE 385 SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCTS OFFERED (SUPPLIED OVERSEAS)
  • TABLE 386 SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCTS OFFERED (SUPPLIED IN INDIA)
  • TABLE 387 SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 388 SERUM INSTITUTE OF INDIA PVT. LTD.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 389 SERUM INSTITUTE OF INDIA PVT. LTD.: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 390 BAVARIAN NORDIC: COMPANY OVERVIEW
  • TABLE 391 BAVARIAN NORDIC: PRODUCTS OFFERED
  • TABLE 392 BAVARIAN NORDIC: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 393 BAVARIAN NORDIC: DEALS, JANUARY 2023-JULY 2026
  • TABLE 394 BAVARIAN NORDIC: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 395 TANABE PHARMA CORPORATION: COMPANY OVERVIEW
  • TABLE 396 TANABE PHARMA CORPORATION: PRODUCTS OFFERED
  • TABLE 397 TANABE PHARMA CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 398 TANABE PHARMA CORPORATION: DEALS, JANUARY 2023-JULY 2026
  • TABLE 399 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW
  • TABLE 400 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED
  • TABLE 401 DAIICHI SANKYO COMPANY, LIMITED: DEALS, JANUARY 2023-JULY 2026
  • TABLE 402 PANACEA BIOTEC: COMPANY OVERVIEW
  • TABLE 403 PANACEA BIOTEC: PRODUCTS OFFERED
  • TABLE 404 PANACEA BIOTEC: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 405 BIOLOGICAL E. LIMITED: COMPANY OVERVIEW
  • TABLE 406 BIOLOGICAL E. LIMITED: PRODUCTS OFFERED (INDIAN MARKET)
  • TABLE 407 BIOLOGICAL E. LIMITED: PRODUCTS OFFERED (INTERNATIONAL MARKET)
  • TABLE 408 BIOLOGICAL E. LIMITED: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 409 BIOLOGICAL E. LIMITED: DEALS, JANUARY 2023-JULY 2026
  • TABLE 410 BIOLOGICAL E. LIMITED: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 411 BHARAT BIOTECH: COMPANY OVERVIEW
  • TABLE 412 BHARAT BIOTECH: PRODUCTS OFFERED
  • TABLE 413 BHARAT BIOTECH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 414 BHARAT BIOTECH: DEALS, JANUARY 2023-JULY 2026
  • TABLE 415 NOVAVAX: COMPANY OVERVIEW
  • TABLE 416 NOVAVAX: PRODUCTS OFFERED
  • TABLE 417 NOVAVAX: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 418 NOVAVAX: DEALS, JANUARY 2023-JULY 2026
  • TABLE 419 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 420 INOVIO PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 421 INOVIO PHARMACEUTICALS: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 422 SINOVAC: COMPANY OVERVIEW
  • TABLE 423 INCEPTA PHARMACEUTICALS LTD.: COMPANY OVERVIEW
  • TABLE 424 VALNEVA SE: COMPANY OVERVIEW
  • TABLE 425 EUBIOLOGICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 426 BIO FARMA: COMPANY OVERVIEW
  • TABLE 427 MICROGEN: COMPANY OVERVIEW
  • TABLE 428 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD: COMPANY OVERVIEW
  • TABLE 429 INDIAN IMMUNOLOGICALS LIMITED: COMPANY OVERVIEW
  • TABLE 430 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 431 VACCINES MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 VACCINES MARKET SEGMENTATION & REGIONS COVERED
  • FIGURE 2 MARKET SCENARIO
  • FIGURE 3 GLOBAL VACCINES MARKET (INCLUDING COVID-19 VACCINES), 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINES MARKET, 2023-2026
  • FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VACCINES MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS IN VACCINES MARKET (EXCLUDING COVID-19 VACCINES), 2026-2031
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN VACCINES MARKET (EXCLUDING COVID-19 VACCINES), IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 8 FOCUS ON VACCINE DEVELOPMENT AND LAUNCHES TO DRIVE MARKET GROWTH
  • FIGURE 9 US AND MULTIVALENT VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE VACCINES MARKET IN NORTH AMERICA IN 2025
  • FIGURE 10 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET DURING 2026-2031
  • FIGURE 11 INTRAMUSCULAR AND SUBCUTANEOUS ROUTE TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 12 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 13 US: NOVEL INFLUENZA A VIRUS CASES, BY SEASON (2010-2011 TO 2025-2026 SEASON)
  • FIGURE 14 MANUFACTURING-RELATED PARAMETERS INCLUDED IN COST MODEL
  • FIGURE 15 US: ESTIMATED NUMBER OF NEW CANCER CASES AND DEATHS BY SITE, 2025
  • FIGURE 16 VACCINES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 17 GLOBAL GDP GROWTH, 2020-2030
  • FIGURE 18 VACCINES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 19 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
  • FIGURE 20 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
  • FIGURE 21 VACCINES MARKET ECOSYSTEM
  • FIGURE 22 AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION, 2024-2026 (USD)
  • FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN VACCINES MARKET
  • FIGURE 24 VACCINES MARKET: PHARMACEUTICAL M&A DEAL ACTIVITY, NUMBER, AND AGGREGATE TOTAL VALUE, 2021-2025
  • FIGURE 25 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS, 2015-2025
  • FIGURE 26 IMPACT OF AI/GEN AI ON VACCINES MARKET
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES
  • FIGURE 28 KEY BUYING CRITERIA, BY END USER
  • FIGURE 29 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
  • FIGURE 30 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
  • FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET, 2021-2025 (USD BILLION)
  • FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET, 2025
  • FIGURE 33 VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 34 VACCINES MARKET: COMPANY FOOTPRINT
  • FIGURE 35 VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 36 EV/EBITDA OF KEY VENDORS
  • FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 38 VACCINES MARKET: PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 39 PFIZER INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 40 GSK PLC: COMPANY SNAPSHOT (2025)
  • FIGURE 41 MERCK & CO., INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 42 SANOFI: COMPANY SNAPSHOT (2025)
  • FIGURE 43 CSL: COMPANY SNAPSHOT (2025)
  • FIGURE 44 EMERGENT: COMPANY SNAPSHOT (2025)
  • FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 46 ASTRAZENECA: COMPANY SNAPSHOT (2025)
  • FIGURE 47 BAVARIAN NORDIC: COMPANY SNAPSHOT (2025)
  • FIGURE 48 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2025)
  • FIGURE 49 PANACEA BIOTEC: COMPANY SNAPSHOT (2024)
  • FIGURE 50 NOVAVAX: COMPANY SNAPSHOT (2025)
  • FIGURE 51 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2025)
  • FIGURE 52 VACCINES MARKET: RESEARCH DESIGN
  • FIGURE 53 VACCINES MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 54 GLOBAL VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
  • FIGURE 55 GLOBAL VACCINES MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025
  • FIGURE 56 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE ANALYSIS, 2025
  • FIGURE 57 VACCINES MARKET: INSIGHTS FROM PRIMARIES
  • FIGURE 58 ILLUSTRATIVE EXAMPLE OF INFLUENZA VACCINES: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025
  • FIGURE 59 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 60 VACCINES MARKET: CAGR PROJECTIONS
  • FIGURE 61 VACCINES MARKET: DATA TRIANGULATION